Please assess the completion status of the following clinical trial:

Trial Title: Clinical Efficacy and Safety Evaluation of Co-administered HGP0904, HGP0608 and HGP0816 in Patients With Hypertension and Dyslipidemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. 19 ≤ age ≤ 75~2. at Visit 1 1) BP: sitDBP ≥ 90mmHg 2) Cholesterol : LDL-C ≤ 250mg/dL, TG \< 400mg/dL~3. at Visit 2 : after TLC (after 4weeks) 1) BP: 80 mmHg ≤ sitDBP \< 110mmHg 2) Cholesterol : following risk category (Cardiovascular Risk category) A : CHD risk factor 0 - 1, 160mg/dL ≤ LDL-C ≤ 250mg/dL B①: CHD risk factor≥2 and 10 year risk \<10%, 160mg/dL ≤ LDL-C ≤ 250mg/dL B②: CHD risk factor≥2 and 10 year risk =10-20%, 130mg/dL ≤ LDL-C ≤ 250mg/dL C : CHD/CHD risk equivalents\* or 10 year risk\>20 ,100mg/dL ≤ LDL-C ≤ 250mg/dL 3) TG \< 400mg/dL 4. Patients understood the contents and purpose of this trial and signed informed consent form~Exclusion Criteria:~1. At Visit 1, BP difference SBP ≥20mmHg or DBP ≥10mmHg~2. Tolerance or Hypersensitivity Angiotensin II receptor blocker or HMG-CoA. reductase inhibitor, Calcium channel blocker(dihydropyridine) or Multi-drug allergy~3. Fibromyalgia, myopathy, rhabdomyolysis or acute myopathy or medical history of adverse effect to statin~4. CPK normal range ≥ 3times~5. Uncontrolled primary hypothyroidism(TSH normal range ≥ 2 times)~6. Renal disease or suspected renal disease (Scr ≥ 2mg/dL, AST or ALT≥2 times)~7. Active gout or hyperuricemia(at Visit 1, uric acid \> 9mg/dL)~8. IDDM or uncontrolled diabetes mellitus (HbA1c\>9%)~9. ventricular arrhythmia~10. medical history~    * severe cerebrovascular disease within 6 months (cerebral infarction, cerebral hemorrhage), hypertension~   * encephalopathy, transient cerebral ischemic attack(TIA)~   * severe heart disease(heart failure of NYHA class III-IV), valvular disease of heart or myocardial infarction and unstable angina~   * angioplasty or coronary artery bypass graft(CABG) surgery within 6months

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Experimental (Type: EXPERIMENTAL): HGP0904 + HGP0608 + HGP0816, once daily
- Active Comparator1 (Type: ACTIVE_COMPARATOR): HGP0904 placebo + HGP0608 + HGP0816, once daily
- Active Comparator2 (Type: ACTIVE_COMPARATOR): HGP0904 + HGP0608 + HGP0816 placebo, once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).